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Rag2/ C
/ mice transplanted with human hematopoietic stem cells (DKO-hu-HSC mice) mimic aspects
of human infection with human immunodeficiency virus type 1 (HIV-1), including sustained viral replication
and CD4 T-cell decline. However, the extent of HIV-1 evolution during long-term infection in these humanized
mice, a key feature of the natural infection, has not been assessed fully. In this study, we examined the types
of genotypic and phenotypic changes in the viral env gene that occur in the viral populations of DKO-hu-HSC
mice infected with the CCR5-tropic isolate HIV-1JRCSF for up to 44 weeks. The mean rate of divergence of viral
populations in mice was similar to that observed in a cohort of humans during a similar period of infection.
Many amino acid substitutions were common across mice, including losses of N-linked glycosylation sites and
substitutions in the CD4 binding site and in CD4-induced epitopes, indicating common selective pressures
between mice. In addition, env variants evolved sensitivity to antibodies directed at V3, suggesting a more open
conformation for Env. This phenotypic change was associated with increased CD4 binding efficiency and was
attributed to specific amino acid substitutions. In one mouse, env variants emerged that exhibited a CXCR4-
tropic phenotype. These sequences were compartmentalized in the mesenteric lymph node. In summary, viral
populations in these mice exhibited dynamic behavior that included sequence evolution, compartmentalization,
and the appearance of distinct phenotypic changes. Thus, humanized mice offer a useful model for studying
evolutionary processes of HIV-1 in a complex host environment.
Animal models of HIV-1 infection are important tools for
studying transmission, replication, and pathogenesis, as well as
therapeutic intervention, of HIV-1 infection. Nonhuman pri-
mates such as rhesus macaques, infected with simian or chi-
meric simian/human immunodeficiency viruses (SIV or SHIV,
respectively), represent well-characterized and highly relevant
models; however, key limitations include expense, genetic vari-
ability of the host animals, and the fact that SIV, while closely
related, is distinct from HIV-1. Therefore, small animal mod-
els that support HIV-1 infection and recapitulate many aspects
of the human infection have been sought using several ap-
proaches.
Recent approaches have involved the use of genetically im-
munodeficient mice that have been reconstituted using human-
derived hematopoietic stem cells (HSC) (known as humanized
mice). Several models have been developed based on this ap-
proach, including Rag2/ C
/ (DKO) and NOD/SCID/
C
/ (NOG or NSG) mice transplanted with human HSC
(DKO-hu-HSC or NOG-hu-HSC mice) (40, 92) and the NOD/
SCID mouse with transplanted human fetal thymus and liver
tissue in addition to HSC (62). These models all support
HIV-1 infection (1, 3, 6, 30, 87, 96, 102; for a review of these
models, see the work of Denton and Garcia [22]). The DKO-
hu-HSC mouse lacks both recombination activating gene 2
(Rag2) and the cytokine receptor common gamma chain (C),
and as a result, it does not generate murine T, B, and natural
killer (NK) cells but supports engraftment of HSC and differ-
entiation of human myeloid and lymphoid lineages. Immune
reconstitution in this model likely involves education of human
T cells in the mouse thymus and dissemination of differenti-
ated human lymphoid subsets into the peripheral blood and to
multiple lymphoid tissues, including lymph nodes, spleen, and
bone marrow (92). The DKO-hu-HSC mouse, along with the
other humanized mouse models, has been used in studies of
transmission (5, 21), pathogenesis (43), and viral inhibition (16,
21, 53, 88, 94).
One important feature of HIV-1 infection is the diversifica-
tion and evolution of the viral genome over the course of
infection. Diversification occurs most prominently in the enve-
lope (env) gene, which encodes the viral surface glycoprotein
(Env). Env mediates viral entry into cells through attachment
to the primary receptor CD4, which primes Env for engage-
ment with a coreceptor, either CCR5 or CXCR4, triggering
virion fusion with the cellular plasma membrane (54). HIV-1
infection is typically established by one or a few CCR5-tropic
(R5) variants that give rise to an initially homogenous viral
population, which then diversifies over the course of chronic
infection (45, 84). Diversification of Env results from immune
selective pressures (27), isolation in or adaptation to different
cellular and anatomical compartments (20, 28, 33, 46, 51), and
selection for altered CD4 affinity (72, 90, 95) and coreceptor
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tropism (26, 39). In many cases, during late-stage infection,
variants emerge from the R5 virus population that are CXCR4
tropic (X4), an event that is often associated with accelerated
CD4 T-cell loss and progression to AIDS (9, 18, 89). In an
effort to determine if any of these aspects of HIV-1 evolution
are exhibited in the humanized mouse model, we examined the
extent of HIV-1 diversification and the types of evolutionary
changes that occur in env in mice infected with CCR5-tropic
HIV-1 for up to 44 weeks.
Sampling of viral env variants from the peripheral blood
plasma over the course of the infection revealed increasing
diversity and divergence of the viral population at rates similar
to those observed in natural infection. Mutations were identi-
fied that affected Env conformation and sensitivity to neutral-
izing antibodies, CXCR4 coreceptor use, and potential
N-linked glycosylation sites. Other mutations potentially af-
fecting the Env phenotype were identified in CD4 binding sites
and CD4-induced epitopes. The patterns of substitutions indi-
cated that certain sites were under selection, particularly in
cases where the same substitution was identified in multiple
mice.
This study demonstrates the potential for studying HIV-1
evolution in the DKO-hu-HSC mouse model and also gives
insight into the types of selective pressures driving HIV-1 env
evolution in this host environment. These findings, while high-
lighting some of the limitations of this model, will help to
inform its appropriate use for studying different aspects of
HIV-1 infection, such as the evolutionary constraints placed on
HIV-1 during natural infection and in the face of pharmaco-
logical and immunological inhibition.
MATERIALS AND METHODS
Model generation. Rag2/ C/ immunodeficient newborn mice were in-
jected intrahepatically with human CD34 hematopoietic stem cells. Two sepa-
rate CD34 cell donors were used to reconstitute mice 5 to 8 and mice 64 and
67 (donors A and B, respectively, in Table 1). After 8 to 12 weeks, immune
system reconstitution was confirmed. HIV-1JRCSF (GenBank accession number
M38429.1) was generated by transfection of 293T cells with an infectious clone
expression plasmid, pYK-JRCSF (52), obtained from the National Institutes of
Health AIDS Research and Reference Reagent Program (ARRRP). Cell-free
supernatant was used to intravenously infect reconstituted mice. Five mice from
cohort A (mice 4 to 8) and four mice from cohort B (mice 63 to 67) were
infected. Mice from each cohort that were successfully engrafted, successfully
infected, and kept alive with active infection for at least 22 weeks were analyzed.
Viral load was monitored for 44 weeks in mice 5 to 8 and for 22 weeks for mice
64 and 67.
As part of an additional study investigating the role of CD4 CD25 Foxp3
T regulatory cells (Treg cells) in HIV-1 infection, mice 6 to 8 were treated at 43
weeks postinfection with denileukin diftitox (also called DAB389IL-2 or Ontak),
which selectively depletes Treg cells (43, 55). Treg cells account for 1 to 4% of
all CD4 T cells in this model, and Ontak treatment usually results in selective
depletion of Treg cells, by as much as 90% (43). Treatment with Ontak corre-
lated with increased immune activation, as measured by CD38 expression, and
Ontak-treated mice also exhibited a greater percentage of infected cells and
greater CD4 T-cell depletion. Ontak treatment may have increased viral rep-
lication, perhaps as an effect of global enhancement of CD4 T-cell activation.
While there were unique evolutionary events observed in individual mice, there
was no clear distinction in the patterns of viral evolution between treated and
untreated animals.
Sample collection. Mice were monitored for peripheral blood viral loads and
CD4/CD8 ratios for up to 44 weeks. Peripheral blood samples (30 l) were
collected at 3, 10, 22, 40, and 44 weeks postinfection. Mice were sacrificed and
tissue was harvested at 22 weeks (mice 64 and 67) and 44 weeks (mice 5 to 8)
postinfection.
Nucleic acid extraction. Viral RNA was extracted from the available volume of
blood plasma (30 l) by use of a QiaAmp viral RNA kit (Qiagen, Valencia,
CA) and was eluted in 60 l distilled water. Total DNA was extracted from
tissue, using a PicoPure DNA extraction kit (Molecular Devices, Sunnyvale, CA).
Pelleted cells extracted from collagenase-treated tissue (about 105 to 106 cells)
were resuspended in 50 l of PicoPure buffer containing proteinase K. The
extraction suspension was incubated at 65°C for 8 h and used directly for PCRs
as described below.
Viral RNA and DNA amplification and sequencing. The 60-l RNA eluate was
reverse transcribed using the Superscript III reverse transcriptase (RT) system
(Invitrogen, Carlsbad, CA) and an oligo(dT) primer. A region of the HIV-1
genome encompassing env through the 3 U3 region was amplified from cDNA
by a limiting-dilution PCR approach (single-genome amplification [SGA]) ini-
tially described by Simmonds et al. (86) and Edmonson and Mullins (24) and
then modified by Palmer et al. (70) and Salazar-Gonzalez et al. (80). Primers and
thermocycling procedures for amplification and sequencing were used as previ-
ously described by Keele et al. (45) but were modified by replacing the down-
stream env amplification primer set with a primer that captures the U3 region,
with the sequence 5-AAGCACTCAAGGCAAGCTTTATTG-3. The same
procedure used for amplifying cDNA was used to amplify the envelope gene
from viral DNAs extracted from tissue samples. Automated sequencing followed
by manual editing of sequences was carried out on SGA amplicons, using the Big
Dye Terminator system (Applied Biosystems, Foster City, CA).
HIV-1 sequencing data from human infections. HIV-1 sequences from human
infections were obtained from the work of Shankarappa et al. (84) and Salazar-
Gonzales et al. (81).
Sequence analysis. Subtype B sequences used for assessment of sequence
conservation at specific sites were accessed through the Los Alamos National
Laboratories HIV Sequence Database (http://www.hiv.lanl.gov). Sequence align-
ments were generated using MAFFT (multiple alignment using fast Fourier
transform) (44). The best-fitting substitution rate model for each alignment
was determined using FindModel, a variation of Modeltest (75), imple-
mented through http://www.hiv.lanl.gov/content/sequence/findmodel/findmodel
.html. Maximum likelihood (ML) phylogenies were generated in PhyML, using
the best-fitting model (GTR or HKY85 in this study), four rate substitution
categories, and the PhyML-determined gamma shape parameter and number of
invariant sites. Potential N-linked glycosylation (PNLG) sites were identified
using N-Glycosite (103), implemented through http://www.hiv.lanl.gov/content
/sequence/GLYCOSITE/glycosite.html. Divergence was determined as the mean
genetic distance of sequences to the founder sequence at a given time point. In the
case of mouse viral populations, the founder sequence was that of HIV-1JRCSF, and
in the case of human viral populations, the “founder” sequence was taken to be the
consensus of sequences sampled at 2 to 5 months postseroconversion for the Shan-
karappa et al. sequence set and an estimated 20 to 24 days postinfection for the
Salazar-Gonzales et al. sequence set. Distances were determined from ML tree
branch lengths by use of Branchlength, implemented through http://www.hiv.lanl.gov
/content/sequence/BRANCHLENGTH/branchlength.html.
Selection analysis was carried out by determining the rates of synonymous and
nonsynonymous substitutions (67, 69). Rates were determined using SNAP (50),
as implemented through http://www.hiv.lanl.gov/content/sequence/SNAP/SNAP
.html. A Wilcoxon signed rank test was used to compare rates of synonymous and
nonsynonymous base substitutions within mouse populations.
Linkage disequilibrium analysis was performed using DNAsp v5 (58). Fisher’s
exact test was used to determine the significance of nonsynonymous nucleotide
substitution associations.
Env phenotype assays. env gene expression vectors were generated from se-
lected amplicons by use of a pcDNA3.1 Directional TOPO expression kit (In-
vitrogen, Carlsbad, CA). 293T cells were cotransfected with env expression vec-
tors and the pNL4-3.Luc.RE luciferase reporter vector (34) (obtained from
ARRRP), using the Fugene transfection reagent (Roche, Mannheim, Germany)
according to the manufacturer’s protocol, to generate pseudovirus. Cells were
washed with phosphate-buffered saline 8 to 12 h after transfection in order to
reduce transfection complex carryover and background luciferase expression in
target cells, which was monitored with an Env-negative control. Virus superna-
tant was collected 48 h after transfection. The coreceptor phenotype was deter-
mined based on detection of luciferase activity in U87.CD4 cells expressing
either CCR5 or CXCR4 (8) (obtained from ARRRP), using a luciferase assay
system kit (Promega, Madison, WI). Pseudovirus was incubated with
U87.CD4.CXCR4/CCR5 cells for 36 to 48 h prior to lysis of cells and measure-
ment of luciferase activity. Coreceptor-dependent viral entry was confirmed
using inhibitory concentrations of AMD3100 (35) (CXCR4 inhibitor) or TAK-
779 (2) (CCR5 inhibitor) (both obtained from ARRRP). Sensitivity to neutral-
ization by the anti-V3 antibodies 447-52D (17) (ARRRP) and 19b (11) (a gift
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from James E. Robinson) was assessed on TZM-BL cells (obtained from
ARRRP), which are permissive to X4 and R5 viruses and contain an integrated,
Tat-responsive luciferase cassette (72). Sensitivity to the anti-CD4 antibody
Leu3a (CD4 Pure) (BD Biosciences, San Jose, CA) was assessed on
U87.CD4.CCR5 cells.
Viral fusion kinetics were measured on U87.CD4.CCR5 cells in a 96-well
format in triplicate. Pseudotyped virus supernatant and cells were cooled to 4°C
and spin inoculated (spinoculated) for 2 h at this temperature to synchronize
entry. Immediately after spinoculation, the medium was removed from cells and
replaced with medium prewarmed to 37°C. The fusion inhibitor T20 (obtained
from ARRRP) was added at the inhibitory concentration of 200 nM at time zero
for the first well and at 5-min intervals for successive wells, for up to 70 min. The
time to one-half maximal entry was used to compare viruses.
Nucleotide sequence accession numbers. The GenBank sequence accession
numbers for sequences generated in this study are GQ412353 to GQ412705.
RESULTS
Diversification and divergence of HIV-1JRCSF over the
course of infection in a mouse model with sustained viral
infection. Six DKO-hu-HSC mice with stable human leukocyte
reconstitution were infected intravenously with HIV-1JRCSF, a
CCR5-tropic isolate of HIV-1 generated from an infectious
molecular clone. Viral infection persisted in all mice over the
period of observation: 44 weeks for mice 5, 6, 7, and 8 and 22
weeks for mice 64 and 67, which received HSC from a different
donor (Table 1). The viral RNA load in the blood exhibited a
slow decay of about 1 log10 over the course of 44 weeks in mice
5 to 8 (Fig. 1), consistent with other reports using this model
and different HIV-1 isolates (3), although the reason for this
drop is not known. A relative decline in CD4 T cells was also
observed (Table 1).
Given that these mice were able to support infection for 22
to 44 weeks, we wanted to know if and to what extent the viral
population had diversified, as is observed in human infections
over a similar period. Viral RNA was extracted from the pe-
ripheral blood plasma and subjected to SGA of the entire env
gene, a limiting-dilution RT-PCR technique designed to facil-
itate direct sampling of viral genomes and to avoid PCR-
generated mutations and recombination. Sequence diversifica-
tion and divergence of HIV-1JRCSF in the peripheral blood
were assessed for a region of env that encodes variable loops 1
through 5 (V1 to V5) of gp120, at the following time points:
weeks 10, 40, and 44 postinfection for mice 5 and 6; weeks 3,
40, and 44 for mouse 8; and weeks 4 and 22 for mice 64 and 67.
The median number of sequences sampled at each time point
was 16.5, and the numbers ranged from 11 to 39 sequences.
A maximum likelihood phylogeny of sequences from the last
time point (week 22 for mice 64 and 67 and week 44 for mice
5 to 8) for each mouse is presented in Fig. 2. Sequences were
generally clustered by mouse, indicating distinct evolutionary
paths that could distinguish mouse viral populations.
For a region of env encompassing C2 to V5, the rate of
divergence from the founder virus in the mice was compared to
that observed in two data sets for infected humans sampled
either prior to seroconversion and at time points 3 to 19
months later (Salazar-Gonzales et al. [81]) or after serocon-
version and at time points 9 to 24 months later (Shankarappa
et al. [84]). In the former study, viral populations from three
subjects were initially sampled prior to seroconversion, at an
estimated 20 to 24 days postinfection and 9 to 16 days prior to
seroconversion. In the latter study, viral populations from 7
subjects were initially sampled within 2 to 5 months after sero-
conversion. In both data sets, the viral populations at the first time
points sampled were relatively homogeneous, and these popula-
tions were compared to those present at the later time points.
Divergence was determined as the mean distance (branch length)
of sequences in a population at a given time point from the
“founder” virus sequence, which was either the consensus of se-
quences sampled at the first time point for the human infections
or HIV-1JRCSF (GenBank accession number M38429.1) for the
mouse infections. The rate of divergence was calculated by using
the mean divergence from the founder of a population at the last
time point measured divided by the time postinfection. The mean
rates of divergence in mice and in the postseroconversion human
data sets were 0.0175%/week (range  0.034 to 0.0043%/week)
and 0.018%/week (range  0.007 to 0.030%/week), respec-
tively, which were statistically indistinguishable (P  0.96) (Fig.
3A). The mean rate of divergence in the pre-to-postserocon-
version data set was also similar (0.015%/week; range  0.004
to 0.026%/week; P  0.706), although slightly lower than that
observed in mice. The mean level of diversity (Fig. 3B) in viral
populations in humans, extrapolated to 44 weeks, was greater
than but still not statistically different from that observed in
mice (P  1 for comparison to the pre-to-postseroconversion
human data set and P  0.5338 for comparison to the post-
FIG. 1. Plasma viral loads over 44 weeks of infection for mice 5 to
8. The DKO-hu-HSC mice were infected intravenously with HIV-
1JRCSF. HIV-1 viremia in plasma samples (copies/ml) from all infected
DKO-hu-HSC mice were measured at 3, 10, 22, 40, and 44 weeks
postinfection for mice 5 to 8 and at 4 and 22 weeks postinfection for
mice 64 and 67.









5 A 9.3 14.69 6.833
6 A 15.1 6.67 0.579
7 A 7.9 4.18 0.317
8 A 15.9 10.91 0.006
64 B 23.7 1.35 0.039
67 B 9.8 1.51 0.263
a Mice were reconstituted with one of two CD34 HSC donors, A and B.
b Percentage of cells expressing human CD45 (hCD45) in the peripheral
blood, determined 11.5 weeks after hCD34 cell transplantation.
c The harmonic mean ratio of CD4 to CD8 T cells in the peripheral blood
for 2 samplings prior to infection.
d Ratio of CD4 to CD8 T cells in the peripheral blood at termination, i.e.,
at 44 weeks for mice 5 to 8 and 22 weeks for mice 64 and 67.
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seroconversion data set). The rates of divergence and diversi-
fication of HIV-1 in mice fell within the distribution of the
rates measured in the two different human cohorts sampled
starting at different points around the time of seroconversion.
These similarities are in spite of the likely absence of an HIV-
1-specific antibody response in the mouse, which is low to
undetectable in this model throughout infection, a selective
pressure that plays a major role in Env divergence and diver-
sification in human infection postseroconversion (27). In this
regard, Western blot analyses of plasmas from the mice used in
this study, taken early and late after infection, were uniformly
negative for reactivity to HIV-1 antigens (data not shown). We
conclude that there is no major difference in the evolutionary
rate of HIV-1 within env in this mouse model over the first 44
weeks from the time of infection from that for an analogous
early stage of human infection, although the selective pressures
in these two settings likely differ (see below).
Features of env sequence evolution in mice. We next wanted
to examine the types and patterns of nucleotide substitutions
that contribute to diversity. One distinctive mechanism that
may contribute to sequence diversity during natural infection is
the activity of the antiviral factor APOBEC3G (A3G) (42),
which can give rise to disproportionate numbers of G-to-A
transitions in the plus-strand sequence in natural infection, in
spite of the A3G antagonist activity of the viral Vif protein,
indicating hypermutation of the nascent minus-strand DNA by
A3G (59, 78, 101). Examining env sequences from mice re-
vealed a subset (1 to 4%) of hypermutated sequences exhibit-
ing a disproportionate number of G-to-A transitions in A3G
target motifs in each mouse, indicating that this mechanism is
at work in this model. This observation also suggests that A3G
may contribute some proportion of G-A transitions observed
at A3G recognition sites in sequences that are not overtly
hypermutated.
A key feature of this model is the isogenicity of hosts recon-
stituted with the same donor. We were interested to see if any
common amino acid substitution patterns emerged in different
mice. Common amino acid substitutions represented in viral
populations of multiple mice likely represent selected changes
rather than mutations that occurred via genetic drift, as might
be the case for substitutions represented in only one mouse.
Substitutions that grew out (i.e., were seen in more than one
sequence either within or between mice) in each mouse viral
population are depicted in Fig. 4 and are categorized by their
potential functional effects, along with the numbers of mice in
which they were detected. Within a 380-amino-acid region
encompassing V1 through V5 and much of conserved region 5
(C5), substitutions at a total of 45 positions grew out. These











FIG. 2. Phylogeny of HIV-1 sequences from all mice. The tree is a
maximum likelihood tree of V1-to-C5 sequences from the peripheral
blood at week 44 for mice 5 to 8 and at week 22 for mice 64 and 67.
Symbols at branch tips indicate the mouse number. Open square,
mouse 5; open triangle, mouse 6; closed triangle, mouse 7; diamond,
mouse 8; closed circle, mouse 64; closed square, mouse 67. The open
circle at the top of the tree indicates the JRCSF input sequence.
Asterisks indicate bootstrap values of 70%. The scale bar indicates
the number of substitutions per site.
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Env (P  0.0001; Fisher’s exact test). However, no insertions
or deletions were observed. Of the substitutions that grew out
in mouse viral populations, 19 were detected in more than one
mouse, and each of the 4 substitutions that were detected in
three or more mice (D167N, N386K/S, N411D/S, and E482K)
were represented in both donor sets (Fig. 4).
Evidence of positive selection can also be obtained by de-
termining the ratio of nonsynonymous to synonymous base
substitution rates (dN/dS). Ratios of 1 and 	1 indicate pos-
itive and negative selection, respectively. For the env region
encompassing V1 to C5, the dN/dS ratio was 1 for viral
populations in mice 6 (1.48) and 8 (1.32), which also showed
the highest levels of divergence (Fig. 3), nearly 1 in mouse 67
(1.03), and 	1 in mice 5 (0.79), 7 (0.82), and 64 (0.57), al-
though the differences between rates of synonymous and non-
synonymous mutations were significant only for mice 6 (P 
0.0126; dN/dS  1.48) and 64 (P  0.0001; dN/dS  0.57). We
interpret these results with caution, because this analysis is
limited in its sensitivity when there are too few substitutions to
provide statistical power or when only a few sites are under
positive selection, which is often the case in Env early in in-
fection.
Substitutions identified at multiple potential N-linked glyco-
sylation sites. Glycosylation of Env at numerous sites has been
shown to play a role in proper protein folding, receptor and
coreceptor engagement (57, 73), and escape from neutralizing
antibodies (15, 47, 97). We identified one substitution, S142N
in mouse 6, that added a PNLG sequon [NX1(S/T)X2, where X
represents any amino acid other than proline (29)] in V1 and
adjacent to a preexisting PNLG site in HIV-1JRCSF, which
remained intact (Fig. 4). In contrast, substitutions that dis-
rupted PNLG sequons were observed at seven positions and
included the following (mean frequencies are indicated in
parentheses): N160K (8%), N187D (36%), N230S (43%),
N241D (5%), N339K/D (8%), N386K/S (86%), N411D/S
(40%), and T413I (36%) (Fig. 4). All substitutions, except
N160K and N241D, were detected by week 10. Substitutions
N339K/D, N386K/S, N411D/S, and T413I were identified in
more than one mouse, suggesting that the loss of glycosylation
at these sites was under some level of selection, although the
low frequency of the N339K/D substitution, at no more than
12%, suggests that selection at this site was weak. The
N386K/S substitution, which rose to the highest frequency in
the three mice in which it was detected (mean, 86%), and the
N339K/D substitution are located in the V4 and C3 regions,
respectively, and are part of the neutralizing antibody 2G12
epitope. Loss of these PNLG sites individually and in combi-
nation has been shown to confer resistance to this antibody
(60, 93). The PNLG sequon composed of N411 and T413,
located in V4, has been shown to covary with a number of
other PNLG sequons and likely plays a role in the glycosylation
of Env as a means of antibody escape (74, 97). The net loss of
PNLG sites was widely distributed across Env, indicating that
the heavy glycosylation of Env observed in natural infection
may not be required for viral persistence in this model and may
reflect the lack of a strong humoral immune response; main-
tenance of these glycosylation sites likely has a fitness cost for
replication.
HIV-1JRCSF evolves to become sensitive to specific anti-V3
antibodies. Previous studies using the DKO-hu-HSC model
have found the humoral immune response to HIV-1 to be
weak (3) or undetectable (1, 30, 102), and we did not detect
any HIV-specific antibodies in the mice in this study. Primary
isolates of HIV-1 passaged in cell culture in the absence of
neutralizing antibody pressure evolve to become sensitive to a
spectrum of heterologous neutralizing antibodies (4, 65, 99).
The antibody 447-52D is specific for a conserved epitope at the
tip of the Env V3 loop and neutralizes viral isolates that are
FIG. 3. Comparison of divergence rates and diversity levels in mice
and humans. Distance measurements were based on branch lengths of
maximum likelihood trees. Symbols for the mouse group in panels A
and B indicate the mouse number. Open square, mouse 5; open tri-
angle, mouse 6; closed triangle, mouse 7; diamond, mouse 8; closed
circle, mouse 64; closed square, mouse 67. (A) Divergence rates in
mice and in human cohorts initially sampled postseroconversion (hu-
man postseroconversion) (86) and preseroconversion (human pre-to-
postseroconversion) (83) were measured for the C2-to-V5 region of
env. For the postseroconversion data set, the mean distance, based on
branch lengths of a maximum likelihood tree, was measured from the
consensus at a time point 2 to 5 months postseroconversion for vari-
ants sampled at time points 9 to 24 months later. Sequences sampled
at the first time point were relatively homogeneous, except for two
subjects who were likely infected with two variants and were removed
from the analysis. For the pre-to-postseroconversion data set, mean
distance was measured from the consensus at time points estimated to
be 20 to 24 days postinfection and 9 to 16 days prior to seroconversion
for variants sampled 3 to 19 months later. Mean distance was divided
by the time between sampling points to obtain the rate of divergence.
For mice, the mean distance was measured from HIV-1JRCSF for vari-
ants sampled at the last time point, at either 22 or 44 weeks postin-
fection. (B) Population diversity is represented as the mean pairwise
distances within populations at or extrapolated to 44 weeks postinfec-
tion, for mouse and pre-to-postseroconversion human samples, or
postseroconversion for the postseroconversion human samples. The
student t test was used to determine P values for differences between
distributions. P values for all comparisons were 0.2.
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known to have a history of cell culture passage, while primary
isolates can encode the epitope but remain largely resistant (7,
17, 83). Sensitivity of cell culture-passaged virus to this and
other V3 antibodies, such as 19b, is attributed to a loss of the
Env conformation that masks the V3 epitope (61, 100). We
were therefore interested in assessing the extent to which HIV-
1JRCSF, which encodes the V3 epitopes but is resistant to 447-
52D, had evolved sensitivity to this antibody. env clones that
included a broad spectrum of substitutions were generated
from the amplicons from five mouse viral populations at the
last time point (week 44 for mice 5 to 8 and week 22 for mouse
64). Screening of the env clones generated from these mice for
expression of an Env protein with sensitivity to 447-52D (as
tested in a pseudovirus assay) revealed a subset of clones in
four of the five mice that encoded Env proteins that were
neutralization sensitive compared to the input virus Env (Fig.
5A). Two mutually exclusive mutations, N165R/K and D167N,
near the base of the V2 loop, appeared to be linked to neu-
tralization sensitivity, as one or the other was present in all
neutralization-sensitive Envs and absent in those that re-
mained resistant (Fig. 5A and B). These mutations were de-
tected early in infection. The D167N mutation was detected at
week 10 in mice 5 and 6, and both N165K/R and D167N
mutations were present in mice 5 and 6 at week 44. Mice 8 and
64 exhibited only the D167N mutation, which was detected in
these mice at 22 and 44 weeks postinfection, respectively. The
frequencies of these mutations in a population were, on aver-
age, 36% and 52% for N165R/K and D167N, respectively.
Neither mutation was detected in mouse 7 or 67. When these
mutations were reintroduced into HIV-1JRCSF env individually,
they rendered the virus relatively neutralization sensitive (Fig.
5C). We also tested these mutants, along with several of the
447-52D-sensitive clones, for sensitivity to another V3-specific
antibody, 19b, and obtained similar results (data not shown).
The frequency with which these substitutions were detected
suggests that viruses replicating in these mice, as with virus
passaged in cell culture, were not under strong selection by
HIV-1-specific antibodies and that these mutations may oth-
erwise confer a selective advantage for an Env function possi-
bly involving increased CD4 binding affinity, CD4 indepen-
dence, or more rapid fusion (38, 48, 64, 66, 77).
In order to determine if increased neutralization sensitiv-
ity was linked to CD4 binding affinity, clones were selected
that represented a range of sensitivities to the anti-V3 an-
tibody, from relatively resistant to highly sensitive. Sensitiv-
ity to competitive inhibition by an anti-CD4 antibody,
Leu3a, was used to evaluate CD4 binding efficiency. Table 2
shows the relative sensitivities of viruses pseudotyped with
selected Env proteins to inhibition of entry by Leu3a. Env
proteins that were highly sensitive to the anti-V3 antibody,
those derived from mouse 6, showed a small but significant
decrease in sensitivity to Leu3a, while the JRCSF I165K and
D167N mutants, which exhibited intermediate sensitivities
to the anti-V3 antibody, exhibited only a marginal decrease
in Leu3a sensitivity. This indicates that these Env proteins
have enhanced CD4 binding. When viral fusion kinetics
were measured in a time-of-addition experiment using T20,
we failed to measure an increase in the rate of entry for any
of these clones (data not shown). Although the mutations at
positions 165 and 167 conferred only a slight increase in
CD4 binding affinity, indicating that other mutations are
likely involved in conferring a stronger phenotype, they are
linked to anti-V3 antibody sensitivity and likely contribute
to a more open Env conformation that potentiates CD4
binding and an increase in replication capacity. This is con-
FIG. 4. Positions and classifications of amino acid substitutions in the V1-to-C5 region of Env. Amino acid numbering on the abscissa
corresponds to the HXB2 reference sequence. Bars on the graph indicate positions of substitutions and the frequency with which substitutions were
identified in a mouse population at the final time point postinfection. Variable loops are shaded in gray. Substitution types are indicated by symbols.
Square, addition of a PNLG site; diamond, loss of PNLG site; open triangle, 95% sequence conservation in subtype B; closed circle, component
of the CD4 binding domain; asterisk, reversion to subtype B consensus; closed triangle, linked to coreceptor tropism. Substitutions at positions 165
and 167 that affected Env conformation and substitutions identified in three or more mice are indicated along with their mean percent abundances
in the population. Substitutions identified in both donor sets are indicated by “AB” (see Table 1). “TC” indicates substitutions associated with
tissue culture adaptation in other studies (see Discussion). Assessment of 95% sequence conservation was based on a random sampling of 300
sequences (one per patient) from the Los Alamos HIV Sequence Database. Sequencing of 30 SGA amplicons from the inoculum revealed four
single point mutations among three amplicons. One of these mutations, at codon 151, was observed later in infection, in mouse 67.
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sistent with the observation that Envs with these mutations
become fixed in multiple mouse viral populations.
When linkage analysis was performed, two sets of muta-
tions were found to be in high linkage disequilibrium with
each other in multiple mouse viral populations. Substitu-
tions at positions 165 and 167 exhibited mutual exclusivity in
the two mice in which both substitutions were present (mice
5 and 6), and each was linked to a different position in the
same PNLG sequon, occupying positions 411 to 413. In
mouse 6, substitutions at positions 165 and 167 were linked
to PNLG site-disrupting substitutions at positions 413 and
411, respectively (P 	 0.0001 for both). In mouse 5, changes
at positions 165 and 413 were also strongly linked (P 	
0.001), although linkage between positions 167 and 411 was
weak. In two other mice (mice 8 and 64), only substitutions
at positions 167 and 411 were present, and in mouse 8, they
were largely coincident in the subset of genomes where they
appeared (P 	 0.01). In mouse 64, while a substitution at
position 167 appeared in 30% of genomes, changes at posi-
FIG. 5. Neutralization sensitivities of selected envelope clones and mutants to 447-52D. (A) Clone names give the mouse number followed by
the clone number (e.g., 5_10). Percent inhibition is indicated for 447-52D antibody concentrations of 10 to 0.1 g/ml. Error bars represent the
ranges for two replicates. SF162c, a neutralization-sensitive chimeric env gene in which the V3 region of HIV-1SF162 was replaced with the V3
region from HIV-1JRFL (71). (B) Alignment of the V2 loops of clones tested for neutralization sensitivity to 447-52D. Positions 165 and 167 are
indicated. (C) Neutralization sensitivity of HIV-1JRCSF with I165R, D167N, or I165K substitution alone.








6_38 40.9 (34.7–48.2) 	0.1
6_39 43.2 (39.3–47.6) 	0.1
JRCSF I165K 35.3 (31.0–40.2) 0.2
JRCSF D167N 33.0 (29.4–37.1) 1.4
7_16 23.2 (19.3–27.7) 10
7_25 23.0 (19.6–27.1) 10
JRCSF 23.5 (19.8–28.0) 10
a The first position in the clone name indicates the mouse number or the
parental clone (for mutants).
b Fifty percent inhibitory concentration (IC50) values were obtained from a
sigmoidal dose-response curve fitted to 8 to 10 concentration data points (3
replicates per data point) ranging from 2 to 104 g/ml.
c IC50 values were obtained from a linear curve fitted to 3 concentration data
points, 10, 1, and 0.1 g/ml.
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tion 411 appeared in all genomes. Weak linkage between
positions in V3 and either position in the 411 sequon were
also observed in mice 6 and 8. In summary, the substitutions
at positions 165 and 167, themselves implicated in alter-
ations of envelope structure, showed linkage to mutations
that disrupted the same distant PNLG site, but the linkage
was to different positions within the PNLG sequon. It seems
likely that the specific amino acid that removes the carbo-
hydrate attachment at position 411 has a context-dependent
effect based on the substitution at position 165 or 167.
Evolution of coreceptor usage. HIV-1 infection is primarily
established by variants that utilize CCR5 as their coreceptor
for entry into target cells (R5 viruses), but in about half of
subtype B chronic infections, viral variants emerge that can use
CXCR4 as their coreceptor (termed X4 viruses) (19, 49). The
sequence of the V3 loop is a strong genetic determinant of, and
can be used to predict, HIV-1 coreceptor phenotype (26, 41,
68). Because HIV-1JRCSF utilizes CCR5 exclusively, we were
interested in determining if this virus had evolved to use
CXCR4 in any of these animals. Six of 39 (15%) sequences
from mouse 6 exhibited an X4-associated genotype, with
amino acid substitutions S11G and E25K in V3 (Fig. 6B), at
sites where variability is linked to coreceptor switching (63). In
addition, nearly all V3 sequences from mouse 6 (92%) also had
an S5N substitution, which represented a reversion to the sub-
type B consensus (Fig. 6B). A serine at this position has been
linked to CCR5 usage (63), indicating that this reversion may be
linked to evolution of an X4 phenotype. These and additional
selected clones from mice 5 to 8 were tested for the ability to
enter indicator cell lines expressing CD4 and either CXCR4 or
CCR5. Consistent with their sequence prediction, the clones from
mouse 6 that exhibited the genetic features of X4 usage were able
to infect a CD4 CXCR4 indicator cell line and were therefore
classified as having an X4 phenotype (Fig. 6A and B). Reintro-
duction of the X4-associated V3 sequence into the original HIV-
1JRCSF env gene was sufficient to confer CXCR4 tropism in the
entry assay (data not shown). X4 variants emerged in the periph-
eral blood late in infection; they were not detected at week 40 (0
of 29 sequences) but were detected at week 43 in 3 of 13 se-
quences (23%). Thus, HIV-1 has the potential to evolve to use
CXCR4 in this model, following an evolutionary path similar to
what is observed in natural infections.
Compartmentalization of phenotypic variants. HIV-1 can
be found in multiple tissue compartments in the course of a
human infection, which in some cases leads to the establish-
ment of isolated or compartmentalized viral populations (98).
We were therefore interested in investigating whether or not
variants were compartmentalized in different tissue compart-
ments in the mouse. Mouse 6 in particular, which harbored an
X4 virus population, provided the opportunity to examine the
tissue distribution of variants with distinct coreceptor pheno-
types. Viral env genes (V1 to V5) from this mouse were suc-
cessfully amplified and sequenced from DNAs extracted from
the spleen (SP), bone marrow (BM), and mesenteric lymphoid
tissue (MLN), using the same limiting-dilution technique em-
ployed for plasma RNA. Attempts to amplify viral DNA from
the thymus were unsuccessful. Phylogenetic analysis of se-
quences recovered from these three tissues, together with se-
quences from peripheral blood plasma, revealed the distinct
clustering of X4 viruses within the tree, which was suggestive of
clonal outgrowth of the X4 variant (Fig. 7). In addition, X4-like
variants comprised 95% of variants identified in the MLN,
indicating compartmentalization of this phenotype in this tis-
sue (P 	 0.0001). Phenotypic testing of a sample of variants
with X4-like V3 sequences from the MLN confirmed their X4
phenotype (data not shown). Variants recovered from the
spleen were phylogenetically intermingled with those from the
peripheral blood and exhibited the same distribution. With
these limited data, we cannot determine if X4 compartmental-
ization in the MLN is due to stochastic seeding of or initial
evolution in this tissue site or if X4 viruses have a selective
advantage in the MLN in this model. However, these data do
FIG. 6. Phenotypic analysis of coreceptor tropism. (A) Relative CXCR4 and CCR5 activities of env clones from four mice at week 44
postinfection in a pseudotype entry assay using U87.CD4 cells expressing either CXCR4 or CCR5. env clones exhibiting X4 usage are boxed and
labeled “dual tropic.” Error bars represent the standard deviations for three replicates. These data are representative of multiple tropism assays.
(B) Alignment of the V3 loops of env clones tested for panel A. Clone names indicate the mouse number, tissue origin (peripheral blood [PB]),
and clone number. Env proteins exhibiting X4 tropism, boxed in panel A and indicated as “dual tropic,” are indicated in the alignment as those
with changes in their V3 loops at positions 11 and 25 associated with the ability to use CXCR4. These variants were identified only in mouse 6
and comprised 15% of the population.
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demonstrate the potential for subpopulations of virus to dissem-
inate, evolve, and replicate independently in different tissues.
Genetic compartmentalization between the MLN and PB
was assessed in mice 7, 8, and 64. Viral DNA was not success-
fully amplified from other mice or other tissues. In mice 7 and
8, sequences were well equilibrated between the PB plasma
RNA and MLN tissue DNA. In mouse 64, a single synonymous
mutation was enriched in the MLN (P  0.0001; Fisher’s exact
test), providing a second example of compartmentalization,
although the overall genetic divergence between the two com-
partments was small (data not shown) and likely not based on
phenotypic differences, at least within the Env protein.
DISCUSSION
Current models being used to study various aspects of HIV-1
infection include the genetically immunodeficient Rag2/
C
/ mouse reconstituted with a human immune system by
transplantation of human hematopoietic stem cells (DKO-hu-
HSC mouse) (1, 3, 6, 30, 102). However, a detailed analysis of
viral diversification and evolution in long-term infections has
not been carried out with this system. In this study, we exam-
ined the viral populations of DKO-hu-HSC mice with sus-
tained infection for up to 44 weeks. We found that HIV-1
diversifies at nearly the same rate as that observed in human
infections. We observed evolution of CXCR4 coreceptor use, a
characteristic of many natural chronic infections. In addition, we
detected evolution toward increased sensitivity to a conformation-
dependent V3 neutralizing antibody, increased CD4 binding af-
finity, and a general loss of N-linked glycosylation sites.
Acute HIV-1 infection in humans is marked by high levels of
viral replication. Within several weeks after infection, the cy-
totoxic T-lymphocyte (CTL) response appears and leads to
suppression of peak viremia (12, 76). Following this initial
immune response, variants emerge that have escaped CTL
detection, marking the beginning of continuing evolution of
HIV-1 in response to this selective pressure (12, 77).
Between 4 and 5 weeks postinfection (typically), HIV-1-spe-
cific antibodies appear (seroconversion), with some antibodies
directed against the Env protein that can potentially select for
neutralization escape variants (25, 27, 91). Selection of im-
mune escape variants results in increasing viral diversity, which
begins after seroconversion and continues into the chronic
stage of infection, although the tempo of immune escape is
highly variable and depends on the strength of the immune
response and the extent of immune dysregulation (27). Thus,
the increasing variability in the env gene observed in human
infection after seroconversion has a large component that is
attributable to escape from immune pressure. In contrast, the
DKO-hu-HSC model appears to lack a robust adaptive im-
mune response to HIV-1 (1, 3, 30, 102). However, we observed
similar rates of divergence and degrees of diversity in compar-
ing viral populations from infected human subjects and DKO-
hu-HSC mice. One interpretation is that the rates of diver-
gence in DKO-hu-HSC mouse and human infections, while
similar, are driven by different selective pressures acting on the
population. For example, the virus may be evolving either in
response to constant immune pressure or as a result of selec-
tion for more efficient Env function in the absence of immune
selection, as has been observed in cell culture (38, 48, 64, 65,
FIG. 7. Maximum likelihood phylogeny of env variants (V1 to C5)
recovered from different tissue compartments in mouse 6. Bootstrap val-
ues of 80% and 50% are indicated by double and single asterisks at
nodes, respectively. Sequences were derived from viral DNA except in the
case of sequences from the peripheral blood, which were from plasma
viral RNA. The tissues of origin of sequences are indicated by symbols.
Triangles, spleen; diamonds, bone marrow; squares, peripheral blood;
closed circles, mesenteric lymph node. An open circle indicates the
JRCSF input sequence. The boxed cluster indicates X4-like V3 se-
quences, which contain substitutions at positions 11 and 25, in addition to
others, and cluster together. A subset of these sequences was phenotyp-
ically tested to confirm tropism. Of the variants in the MLN, 95% con-
tained an X4-like V3 sequence, indicating compartmentalization of this
phenotype in this tissue in mouse 6 (P 	 0.0001).
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77), or perhaps also in the late stage of infection associated
with immunodeficiency. The emergence of the same amino
acid substitutions in multiple mice, particularly those that were
linked to a phenotype such as enhanced CD4 binding or loss of
glycosylation sites, was interpreted as evidence of positive se-
lection. Analysis of selection based on the relative rates of
synonymous (dS) and nonsynonymous (dN) mutations across
the V1-to-C5 region revealed no consistent pattern. However,
this type of analysis is compromised when too few synonymous or
nonsynonymous mutations have accumulated to lend enough
power to the analysis or if only a few sites are under strong
positive or negative selection. For this model and over this period,
the per-codon dN/dS rate ratio could not be determined reliably
because of a lack of mutations at synonymous sites.
Some of the patterns of mutations were also similar to those
observed in humans, with most substitutions concentrated in
the variable loops and with the detection of G-to-A hypermu-
tations. However, evolution in this model is distinguished from
natural infection by the quality of some mutations that grew
out in the population. We observed that a number of Env
variants isolated from several mice exhibited increased sensi-
tivity to V3-specific antibodies such as 447-52D, which has
been shown to be dependent on Env conformation and gen-
erally inactive against primary isolates, presumably as a result
of occlusion of the V3 epitope in the wild-type, non-receptor-
bound conformation of Env (7, 48). Specifically, we observed
two mutations in V2 that were selected in most mice and
resulted in amino acid substitutions I165R and D167N. We
found that all of the viruses tested that evolved neutralization
sensitivity to 447-52D had one of these two substitutions and
that either of these alone, when reintroduced into the parental
virus, HIV-1JRCSF, rendered the virus more sensitive to neu-
tralization. Variants with increased anti-V3 antibody sensitivity
also exhibited increased resistance to competitive inhibition by
the anti-CD4 antibody Leu3a. This was interpreted as an in-
creased CD4 binding efficiency.
Both 165R and 167N substitutions are represented, at ap-
proximate frequencies of 3% and 12%, respectively, in the
HIV Sequence Database (Los Alamos National Laboratories),
whereas the most common amino acids at these positions, I165
and D167, are both found at frequencies of about 67%. These
sites therefore exhibit some variability in human infections,
and substitutions at these sites, along with other mutations that
affect Env conformation, may be markers of a loss of robust
humoral immune pressure in late-stage disease, although a
direct link has yet to be made for natural infections. These
substitutions have, however, been identified in several studies
of virus passaged in cell culture (64, 77, 85, 99). While all of
these studies found one or both of these substitutions to be
linked to increased CD4 binding affinity (or sensitivity to CD4
mimics), the effects that these substitutions have on sensitivity
to V3 antibodies in particular vary with the genetic background
and the presence of different coevolving substitutions. In our
study, the I165R/K and D167N substitutions appear to be
mutually exclusive, and their appearance together or in com-
bination with other substitutions may alter their neutralization
phenotype. It is likely that these substitutions, along with oth-
ers observed in viruses that have been passaged in cell culture
systems, represent evolution toward heightened Env function
through increased CD4 binding affinity or evolution toward
CD4 independence, in the absence of neutralizing antibodies,
as postulated previously (48, 65, 77). Further studies are re-
quired to ascertain whether or not these types of mutations are
selected in people during profound immunosuppression and if
they are linked to other phenotypes, such as CXCR4 tropism,
that appear in late-stage disease.
We also observed an overall loss of specific PNLG sites in
multiple mice. Mutations that resulted in the loss of PNLG
sites included sites that have been demonstrated to be con-
served or selected in a long-term infection in a simian/human
immunodeficiency virus model (N339 and N386) (10). Other
PNLG sites that were lost have been identified as central in a
network of coevolving PNLG sites (N411) (74). The loss of the
N386 site, which was observed at a high frequency in three
mice, has been implicated in enhancing HIV-1 replication in
macrophages, which express low levels of CD4 and likely re-
quire changes in Env that increase CD4 affinity in order to be
infected efficiently (23). Thus, the observed losses of N-linked
glycosylation sites in mice, as with the changes affecting neu-
tralization by V3 antibodies, also might represent selection for
changes in Env that increase infectivity in the absence of neu-
tralizing antibodies.
Another feature of natural HIV-1 infection is the emer-
gence, usually late in chronic infection, of variants that use
CXCR4 as a coreceptor. This occurs in about 50% of individ-
uals infected with subtype B HIV-1 (19, 49). While this phe-
notypic switch in the population often coincides with a rapid
drop in CD4 T-cell count and with disease progression (19),
the selective pressures driving this switch are not clear. A
stochastic model where the appearance of X4 variants is lim-
ited by the chance occurrence of the right combination of
mutations does not explain their emergence in humans, where
the host likely also has to be immunodeficient (32, 36, 49). In
one infected DKO-hu-HSC mouse, we detected variants that
could use CXCR4 as their coreceptor in addition to CCR5.
These variants had distinct V3 sequences that were indicative
of CXCR4 usage and were detected at weeks 43 and 44 but not
at week 40. Coincidentally, 3 days prior to the detection of X4
variants, Ontak treatment (see Materials and Methods) was
administered, which resulted in Treg cell depletion and in-
creased T-cell activation. Ontak treatment may therefore have
played a role in creating an environment that potentiated X4
virus emergence in the periphery. However, it is also likely that
the X4 variant preexisted in the MLN, the tissue in which it was
found to be compartmentalized 1 week later. Only one of three
mice treated with Ontak developed detectable X4 virus, and no
other biological characteristic of the virus examined in this
study could be attributed to an Ontak treatment effect. Early
steps in the evolution of CXCR4 tropism may require the same
conformational changes that render the virus sensitive to spe-
cific antibodies (14). A small effective population size in these
mice compared to that in humans could also partly explain the
emergence and outgrowth of X4 variants following a stochastic
process (13, 79). Nonetheless, this animal model provides the
opportunity to explore further the link between X4 emergence
and other Env phenotypes that evolve in the absence of a
robust immune response.
Examination of the tissue distribution of variants in the
mouse in which the X4 virus emerged showed that 95% of
variants in the MLN were X4 viruses, compared to 15% in the
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peripheral blood and 22% in the spleen. While it is possible
that apparent compartmentalization of X4 variants in the
MLN was a result of chance seeding, there may also be a
selective advantage for X4 viruses in this compartment. Previ-
ous studies have identified the thymus as a likely environment
for X4 virus selection due to the high levels of CXCR4 ex-
pressed on resident T cells (82). In contrast, the MLN in
wild-type mice is responsible for linking both inductive and
effector sites of the gut-associated lymphoid tissue (GALT),
such as Peyer’s patches, the lamina propria, and mucosal epi-
thelium. As such, MLNs normally harbor a large population of
activated T cells, predominantly with a memory phenotype,
expressing high levels of CCR5. It is the large number of
activated CD4 CCR5 T cells found in the GALT that are
thought to support establishment and high levels of replication
of the CCR5-tropic viruses responsible for initial infection.
Indeed, this tissue is decimated during peak viremia in the
acute stage of infection (31, 56). Thus, it is unclear how
CXCR4-tropic viruses would have an advantage in this envi-
ronment under normal conditions. However, the MLN in this
model, which is populated by human T cells, may represent a
different environment than that seen in healthy humans or
wild-type mice. The GALT has been shown to be underdevel-
oped in this model (37), indicating that the MLN may not be
populated by the same CD4 T-cell subsets present in this
tissue in a normal individual. Further exploration is required to
assess more fully the cellular subsets populating this and other
compartments in this model and the effects that they have on
the selection of viruses with different phenotypes.
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